those dollars are those of citizen tax payers, should be subject to at least occasional scrutiny and stock-taking (Joyner, Paneth, and Ioannidis 2016). This Special Issue of Perspectives in Biology and Medicine is an attempt to do just that: to ask whether the massive investment of money, equipment and human scientific talent that has been poured into studying the human genome under the assumption that this enormous scientific endeavor will advance human health has been worth it thus far, and whether it is likely to bear fruit in the future The expression that best encapsulates the goal of using genomic information to alter trajectories of disease has varied from time to time in the 15 years since the completion of the Human Genome Project (HGP) in 2003. “Personalized medicine” held sway for the first few years, but that term has now been eclipsed by “precision medicine.” Whichever term is used, the underlying principle is much the same, namely, that what modern medicine most lacks is the incorpo-

中文翻译：

---

编辑对特刊的介绍

这些钱是公民纳税人的钱，应该至少偶尔接受审查和盘点（Joyner、Paneth 和 Ioannidis，2016 年）。本期《生物学和医学展望》特刊正是试图做到这一点：询问是否在假设这项巨大的科学努力将推进的情况下，投入大量资金、设备和人类科学人才来研究人类基因组迄今为止，人类健康是值得的，以及它是否可能在未来开花结果 最能概括利用基因组信息改变疾病轨迹这一目标的表达方式在自该研究完成后的 15 年中不时发生变化。 2003 年人类基因组计划 (HGP)。“个性化医疗”在最初几年占据主导地位，但是这个词现在已经被“精准医学”所取代。无论使用哪个术语，其基本原理都大致相同，即现代医学最缺乏的是结合